Madrigal Pharmaceuticals, Inc. - Common Stock - Çeyreklik Bilanço (NASDAQ:MDGL) | MetaTrader

Tam grafiği aç Full chart

Haberler

Madrigal, Rezdiffra verilerini EASL Kongresi 2026’da sunacak

Truist, Madrigal Pharmaceuticals hissesi için hedef fiyatı yükseltti

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

Wolfe Research, Madrigal hissesi için Peerperform görüşünü korudu

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?